One of the main features of Grand Rounds in Urology™ (GRU) programming is interactive engagement among medical professionals and industry. Through virtual online on-demand education programs and live CME conferences, we strive to bring together a community of urology and oncology professionals to exchange knowledge and discuss best practices for future directions in urology. Our program designs include brief lectures, case presentations, panel discussions, point-counterpoint debates, and audience response technology. Through this professional discourse, GRU aims to improve physician professional development and, ultimately, patient outcomes.
The IBCU 2025 Expert Forum is a closed-format, invitation only event that will bring together a multi-disciplinary group of academic and community bladder cancer experts to discuss and debate the most challenging questions in all areas of bladder cancer. The meeting will be held December 6-8, 2024 in Dallas, Texas, immediately following Society of Urologic Oncology annual meeting. A faculty of 30 bladder experts will discuss the latest clinical data and real-world clinical evidence to determine the impact on management of patients with bladder cancer. Multiple interactive sessions will be designed by national experts in the field to cover the most thought-provoking and contemporary questions facing the oncology community today. Each session will include open debate and discussion followed by formal voting by the multidisciplinary panelists. A peer-reviewed article is planned for publishing the consensus statement of the findings from the IBCU 2025 Expert Forum.
The International Prostate Cancer Update (IPCU), founded in 1991, is a multi-day, CME-accredited conference focused on prostate cancer treatment updates, with international faculty providing attendees a variety of viewpoints and how-to instruction. IPCU will offer interactive participation through lectures, panel discussions, debates, clinical trial updates, and case reports. This conference is led by expert physicians and is designed for urologists, medical oncologists, radiation oncologists, and other healthcare professionals involved in the diagnosis and treatment of prostate cancer.